While targeting of IL-5 or its receptor is an effective, additive therapy in eosinophilic asthma, clinical trials and our current study suggest that isolated blockade of IL-5 signaling is insufficient to capture the entirety of the inflammatory cascade in EoE.24 The gene discussed is IL5; the disease is eosinophilic esophagitis.